Ribosomal Protein L22 (RPL22) Antikörper

Antigen: Ribosomal Protein L22 (RPL22)

Synonyme: EAP, HBP15, HBP15/L22

Klonalität: Polyklonal

Wirt: Ziege

Applikation: ELISA

Produktnummer: ABIN238580

Produktbeschreibung

Weitere Bezeichnung: Ribosomal protein L22

Gen-ID: 6146, 19934 (mouse), 81768 (rat)

Immunogen: C-SKESYELRYFQINQ

Format: Affinity-purified

Beschreibung: All names and symbols: RPL22, ribosomal protein L22, EAP, HBP15, HBP15/L22, 60S ribosomal protein L22, EBER-associated protein, Epstein-Barr virus small RNA-associated protein, Epstein-Barr-encoded RNA-associated protein, heparin-binding protein 15, heparin-binding protein HBp15. Official Symbol: RPL22 . RefSeq number(s): NP_000974.1

Spezifität: Human, Mouse, Rat

Anwendungen

Applikationshinweise: Peptide ELISA: antibody detection limit dilution 1:16,000. Western Blot: Preliminary experiments gave bands at approx 17-18kDa and 25kDa in Human Liver lysates after 0.5µg/ml antibody staining. Please note that currently we cannot find an explanation in the literature for the bands we observe given the calculated size of 14.8kDa according to NP_000974.1. Both detected bands were successfully blocked by incubation with the immunizing peptide (and BLAST results with the immunizing peptide sequence did not identify any other proteins to explain the additional bands). We would appreciate any feedback from people in the field - have any results been reported with other antibodies/lysates? Have any further splice variants/modified forms been reported?

Reinigung: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Buffer: Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

Lagerung: Aliquot and store at -20°C. Minimize freezing and thawing.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Anderson, Lauritsen, Hartman et al.: "Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53-dependent checkpoint." in: Immunity, Vol. 26, Issue 6, pp. 759-72, 2007 (PubMed).